The advisory group said that new combinations should aim to stimulate an antibody response to mutants (XP1.5) or (XP1.16), adding that other formulations that stimulate an antibody response neutralizing the effect of (X) strains could also be considered. Babe).
The group suggested that the original COVID-19 strain should not be included in future vaccines, based on evidence that the original virus no longer circulates in humans and that vaccines targeting the strain produce ” very low or undetectable levels of neutralizing antibodies” due to the currently prevalent mutations.
COVID-19 vaccine makers, such as Pfizer/BioNTech, Moderna, and Novavax, are already developing versions of their vaccines that target XBB1.5 and other currently prevalent mutations.
The bivalent boosters developed and distributed last year targeted two different strains, the Omicron variant and the original virus.
The advisory group said currently approved vaccines should continue to be used in accordance with WHO recommendations.
At the end of March, the organization revised its recommendations for the coronavirus vaccination, noting that healthy children and adolescents do not necessarily need an injection, but that older and at-risk groups should receive an injection. booster six to 12 months after their last vaccine.
The latest recommendations come about two weeks after the World Health Organization ended the global COVID-19 emergency.
Read the Latest World News Today on The Eastern Herald.
